Paulo R Shiroma

Dr. Paulo R Shiroma


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2014 in Journal of Affective Disorders
Verified
Journal Article
Closed access
PSPaulo R Shiroma
Paulo R Shiroma
BJBrian Johns
Brian Johns
MKMichael Kuskowski
Michael Kuskowski
JWJoseph Wels
Joseph Wels
PTPaul Thuras
Paul Thuras
KLKelvin O. Lim
Kelvin O. Lim

25 June 2014 in International Journal of Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
CAC. Sophia Albott
C. Sophia Albott
BJBrian Johns
Brian Johns
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
KLKelvin O. Lim
Kelvin O. Lim
The N-methyl-D-aspartate glutamate receptor antagonist ketamine has demonstrated rapid antidepressant effects in treatment-resistant depression (TRD).

26 June 2020 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
CAC. Sophia Albott
C. Sophia Albott
CEChristopher Erbes
Christopher Erbes
KLKelvin O. Lim
Kelvin O. Lim
The strategy of repeated ketamine in open-label and saline-control studies of treatment-resistant depression suggested greater antidepressant response beyond a single ketamine. However, consensus guideline stated the lack of evidence to support frequent ketamine administration. We compared the efficacy and safety of single vs. six repeated ketamine using midazolam as active placebo. Subjects received either six ketamine or five midazolam followed by a single ketamine during 12 days followed by up to 6-month post-treatment period. The primary end point was the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at 24 h after the last infusion. Fifty-four subjects completed all six infusions. For the primary outcome measure, there was no significant difference in change of MADRS scores between six ketamine group and single ketamine group at 24 h post-last infusion. Repeated ketamine showed greater antidepressant efficacy compared to midazolam after five infusions before receiving single ketamine infusion. Remission and response favored the six ketamine after infusion 4 and 5, respectively, compared to midazolam before receiving single ketamine infusion. For those who responded, the median time-to-relapse was nominally but not statistically different (2 and 6 weeks for the single and six ketamine group, respectively). Repeated infusions were relatively well-tolerated. Repeated ketamine showed greater antidepressant efficacy to midazolam after five infusions but fell short of significance when compared to add-on single ketamine to midazolam at the end of 2 weeks. Increasing knowledge on the mechanism of ketamine should drive future studies on the optimal balance of dosing ketamine for maximum antidepressant efficacy with minimum exposure.

4 April 2014 in International Journal of Geriatric Psychiatry
Verified
Journal Article
Closed access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
PTPaul Thuras
Paul Thuras
BJBrian Johns
Brian Johns
KLKelvin O. Lim
Kelvin O. Lim

1 December 2020 in Journal of Affective Disorders
Verified
Journal Article
Closed access
PSPaulo R Shiroma
Paulo R Shiroma
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
CAC. Sophia Albott
C. Sophia Albott
CEChristopher Erbes
Christopher Erbes
KLKelvin O. Lim
Kelvin O. Lim

10 November 2020 in The Journal of Clinical Psychiatry
Verified
Journal Article
Open access
PDF file
PSPaulo R Shiroma
Paulo R Shiroma
PTPaul Thuras
Paul Thuras
JWJoseph Wels
Joseph Wels
CEChristopher Erbes
Christopher Erbes
SKShannon Kehle-Forbes
Shannon Kehle-Forbes
MPMelissa Polusny
Melissa Polusny
Prolonged exposure is a gold-standard trauma therapy, but trials in military populations show not all patients experience symptom improvement. This 10-week pilot looked at the feasibility of combining ketamine and prolonged exposure for better outcomes.